Eisai files marketing authorization applications for lecanemab in Europe and Japan

Published on January 19, 2023

Eisai has submitted marketing authorization applications for lecanemab in Europe and Japan as it builds up its global plans for the Alzheimerâs drug, which was approved in the US earlier this month.

Continue reading on website
Other news

Resilience to expand global footprint, collaborating on first GMP biopharma facility in UAE

January 19, 2023
National Resilience has secured an equity investment from Mubadala, an Abu Dhabi sovereign investor. The amount was not disclosed.

Cisco to Launch Manufacturing Operations in India

May 12, 2023
Cisco says that this manufacturing investment will lead to over $1 billion for India in combined domestic production and exports over the next few years.